Investors Face August Deadline in GeneDx Securities Lawsuit

The litigation centers on claims that GeneDx issued materially false statements regarding its acquisition of Fabric Genomics. Following the disclosure of the impairment loss and revised financial outlook, the company’s stock plunged by $33.42 per share. Investors seeking to represent the class must demonstrate the largest financial interest, though no minimum loss threshold exists to participate in the underlying action.

Under the Private Securities Litigation Reform Act, the court will appoint a lead plaintiff to oversee case strategy and settlement negotiations. While lead plaintiffs provide direct oversight, they do not incur out-of-pocket costs, as legal counsel operates on a contingency basis. Those who choose not to seek lead status remain as absent class members and do not need to take action before the August deadline to preserve their rights to potential future recoveries. Attorney Joseph E. Levi, representing the firm SueWallSt, stated that selecting an engaged plaintiff with significant losses is vital given the scale of the recent market losses.